StarCaps recall expanded
This article was originally published in The Tan Sheet
Executive Summary
Balanced Health Products expands its voluntary recall of StarCaps Diet Systemto include additional lots - numbers 12/2009-82866 and 12/2010-8301 - because the capsules in the 30-count bottles contain the undeclared ingredient bumetanide, a diuretic that can cause serious fluid and electrolyte loss. The firm says in a Dec. 8 release it believes an additional lot of raw material was contaminated with bumetanide in Lima, Peru. The company suspended StarCaps shipments after National Football League players alleged the product contained bumetanide, which can mask steroid use (1"The Tan Sheet" Nov. 3, 2008, In Brief)
You may also be interested in...
StarCaps shipping stopped
Los Angeles-based marketer Nikki Haskell suspends shipping the weight-loss supplement after a National Football League player alleged Oct. 28 that the product was tainted with bumetanide, a diuretic the NFL banned because it may mask steroid use. In an e-mail, StarCaps said it is aware of the lawsuit filed in New Jersey federal court by New Orleans Saints player Jamar Nesbit and is taking steps to ensure customers receive a safe and effective product. Nesbitt served a four-game suspension after he tested positive for the banned substance. Nesbitt did not appeal the suspension, but another Saints player who also tested positive for bumetanide after using StarCaps is appealing his suspensions. According to ads, StarCaps contains papaya, garlic, valerian, corn spices, papain, magnesium carbonate and magnesium oxide. Nesbitt's lawsuit comes as Congress presses for tighter regulation of supplements, partly due to athletes' complaints about products tainted with steroid ingredients. Industry says supplements are a scapegoat for intentional steroid use
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.